From San Francisco, at the American Society of Hematology’s 42nd annual meeting.
When STI-571 first made news in 1999, it seemed almost too good to be true. In patients with low-grade chronic myelogenous leukemia (CML), it seemed to kill tumor cells like a heatseeking missile destroys a target (SN: 12/11/99, p. 372). Now, further testing of STI-571, called Glivec by Novartis Oncology of East Hanover, N.J.,
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.